Nanobiotix SA

NANO

Company Profile

  • Business description

    Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.

  • Contact

    60 Rue de Wattignies
    Paris75012
    FRA

    T: +33 140260470

    https://www.nanobiotix.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    108

Stocks News & Analysis

stocks

Tesla’s stock is in trouble, but this fund manager sees a comeback in 2026

Tesla’s challenges echo past issues the company has overcome, says Zevenbergen’s Joe Dennison.
stocks

Cheap ASX energy play boasts strong cash flows and balance sheet

Markets appear overly bearish on the company despite the company having attracting growth options.
stocks

Market overreacts to earnings miss from moated ASX retailer

Our forecast recovery is off to a slow start but the sell-off appears to have gone too far.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,245.0066.30-0.71%
CAC 407,843.04126.65-1.59%
DAX 4024,273.1289.97-0.37%
Dow JONES (US)45,282.47349.27-0.77%
FTSE 1009,321.4012.200.13%
HKSE25,829.91490.771.94%
NASDAQ21,449.2947.24-0.22%
Nikkei 22542,807.82174.530.41%
NZX 50 Index13,079.5036.740.28%
S&P 5006,439.3227.59-0.43%
S&P/ASX 2008,972.4071.70-0.79%
SSE Composite Index3,883.5657.801.51%

Market Movers